Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Thermo Fisher Scientific Inc.. A complete text table follows the diagram.
The broadest revenue engine sits in lab products and biopharma services, while Life Sciences Solutions contributes the company's largest segment profit pool
Swipe to explore
All principal flows are reported. Net interest and other expense is shown as a $362M arithmetic residual needed to bridge reported operating income plus interest income to reported pretax income; individually rounded statement lines show $354M of interest expense and $9M of other expense.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Lab products & biopharma services | 1 | $6.0B | 54% of company revenue |
| Life Sciences Solutions | 1 | $2.2B | Bioproduction and biosciences |
| Analytical Instruments | 1 | $1.7B | Chromatography, mass spec and microscopy |
| Specialty Diagnostics | 1 | $1.1B | Clinical and immunodiagnostics |
| Revenue | 2 | $11.0B | Global science-services platform |
| Operating income | 3 | $1.9B | 16.9% operating margin |
| Operating cost base | 3 | $9.1B | Products, services, people and R&D |
| Interest income | 3 | $233M | Cash and investments |
| Operating profit plus interest | 4 | $2.1B | Before financing and other items |
| Income before tax | 5 | $1.7B | 15.8% of revenue |
| Net interest & other expense | 5 | $362M | Arithmetic residual from rounded lines |
| Income after tax | 6 | $1.7B | Before equity-method loss |
| Income tax | 6 | $70M | 4.0% reported effective rate |
| Net income | 7 | $1.7B | After unconsolidated entities |
| Equity-method loss | 7 | $8M | Unconsolidated entities |
| Thermo Fisher net income | 8 | $1.7B | Attributable to the company |
| Noncontrolling interests | 8 | $5M | Subsidiary ownership |
| From | To | Value |
|---|---|---|
| Lab products & biopharma services | Revenue | $6.0B |
| Life Sciences Solutions | Revenue | $2.2B |
| Analytical Instruments | Revenue | $1.7B |
| Specialty Diagnostics | Revenue | $1.1B |
| Revenue | Operating income | $1.9B |
| Revenue | Operating cost base | $9.1B |
| Operating income | Operating profit plus interest | $1.9B |
| Interest income | Operating profit plus interest | $233M |
| Operating profit plus interest | Income before tax | $1.7B |
| Operating profit plus interest | Net interest & other expense | $362M |
| Income before tax | Income after tax | $1.7B |
| Income before tax | Income tax | $70M |
| Income after tax | Net income | $1.7B |
| Income after tax | Equity-method loss | $8M |
| Net income | Thermo Fisher net income | $1.7B |
| Net income | Noncontrolling interests | $5M |